Copyright
©The Author(s) 2022.
World J Hepatol. Apr 27, 2022; 14(4): 670-681
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.670
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.670
Ref. | Study | Intervention | Route of FMT administration | n | Mean MELD score | Follow-up | |
Bajaj et al[29], 2019 | Phase I | Treatment arm | FMT + SOC | Enema | 10 | 12.5 | 5 mo |
Control arm | SOC | 10 | 12.5 | 5 mo | |||
Bajaj et al[28], 2017 | Phase I | Treatment arm | FMT | Enema | 10 | 13.2 | 5 mo |
Control arm | SOC | 10 | 12 | 5 mo | |||
Woodhouse et al[33], 2019 | Phase III | Treatment arm | FMT + Lactulose | NJ tube | 13 | 12.88 | 3 mo |
Control arm | SOC | 5 | 12.88 | 3 mo | |||
Bloom et al[81], 2019 | Phase II | Treatment arm | FMT | Oral | 7 | 13.9 | 1 mo |
Control arm | SOC | 3 | NA | 1 mo | |||
Mehta et al[30], 2018 | Case series | FMT | Colonoscopy | 10 | 18 | 20 d | |
Kao et al[32], 2016 | Case report | FMT | Colonoscopy | 1 | 10 | 7 d |
- Citation: Hoilat GJ, Suhail FK, Adhami T, John S. Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol 2022; 14(4): 670-681
- URL: https://www.wjgnet.com/1948-5182/full/v14/i4/670.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i4.670